Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmutinib in T790M-positive NSCLC
NCT04510415Phase 1Terminated
- Sponsor
- Hanmi Pharmaceutical
- Start
- Mar 2018
- Primary completion
- Dec 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olmutinib in non-small cell lung cancer (NSCLC), sponsored by Hanmi Pharmaceutical. Primary endpoint: Objective Response Rate at 24 months. Started Mar 2018; status: terminated.
02
Drugs
olmutinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04510415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510415.